You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Affordable wireless recording for mice
SBC: Jinga-hi Inc. Topic: 101Project Summary Mice offer a powerful genetic model system, thus are the single most used animal model in neuroscience. Despite potential benefits of wireless recording (more flexible, safer, and more natural in vivo neural recording), adoption of wireless recording in the neuroscience community for mice for a wider neuroscience community had been slow, due to the engineering complexity to enable ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Material-guided delivery and local activation of bioorthogonal prodrugs
SBC: TAMBO, INC. Topic: 300ABSTRACT Systemic administration of small molecule therapeutics to treat disease can be ineffectiveand even hazardousbecause the drugs distribute widely in the bodyThis lack of site specificity means large systemic doses are needed to achieve effective concentrations in the diseased tissuesbut these high doses often result in nonspecific toxicityRoughlyinhospitalized patients experience adverse dr ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a fixed-dose combination therapy for the treatment of chronic musculoskeletal pain
SBC: NeuroCycle Therapeutics, Inc. Topic: NIAMSPROJECT SUMMARY Non steroidal anti inflammatory drugsNSAIDsare a first line pharmacologic pain therapy for chronic musculoskeletal painand rheumatoid arthritisRAand moderate to severe osteoarthritisOAspecificallyHoweverinsufficient pain relief by NSAID monotherapy has encouraged the use of combination therapyCombinations of NSAIDs plus weak opioids are widely used although objective evidence for e ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Preclinical characterization of a novel neuropeptide for inducing "on-demand" voiding
SBC: Dignify Therapeutics LLC Topic: 105PROJECT SUMMARYABSTRACTSpinal cord injurySCIaffects an estimatedAmericansDamage to nerves in the spinal cord can result in a loss of voluntary control over bladder and bowel function that often produces both incontinence and retention of urine and stools in the same patientThe standard of care for urine retention is bladder catheterization to void urinewhich may produce urinary tract infectionsUTI ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Whole-organ bioreactor with integrated nondestructive 3D molecular imaging
SBC: Sonovol, Inc. Topic: NHLBIAbstract Significance: Donor tissue shortage remains a critical problem in lung transplantation. Recent advances in tissue engineering have allowed for the possibility of generating bioengineered lungs from decellularized organ scaffolds. These scaffolds, created from the donor’s tissue, become functionalized after recellularization with a patient’s own cells. However, translation of whole-lun ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders
SBC: Second Genome, Inc. Topic: NIDADespite a wealth of continued funding and ever emerging advancements in diagnostic and therapeutic technologies, the burden of central nervous system (CNS) disorders remains substantial. The cost of Substance Use Disorder (SUD) alone is estimated at andgt; $181 billion (2002). The findings of numerous efforts tasked with identifying risk factors and causative agents of SUD suggest that vulnerabili ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a multiplex peptide array to identify patients with an autoantibody signature for chronic pain
SBC: AFFINERGY, LLC Topic: NIDASUMMARY ABSTRACT Chronicnon cancer pain is a significant unmet health need worldwideThe prevalence of chronic pain among adults in the United States has been estimated at betweenandThe personal toll of living with chronic pain is immenseand the economic impact can be devastatingOne of the most widely used treatments for chronic pain is opioid analgesicsWhile the appropriate use of opioids can be a ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing a High-throughput Bioprinting Platform for 3D iPSC-derived Liver Tissues for Early Drug Screening
SBC: Allegro 3D, Inc. Topic: NIBIBSummaryCurrent drug discovery and development practices have resulted in considerably long development time frames and low success rates of new drugs reaching marketFew improvements on efficiency and poor cost versus benefits in Randamp D have also caused post approval costs as high as $billion inTogetherthese factors drive the demand to improve current practices and turn to new innovative technol ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Using Virtual Reality Psychological Therapy to Develop a Non-Opioid Chronic Pain Therapy
SBC: COGNIFISENSE, INC. Topic: 600Project SummaryAbstract Chronic pain affects overmillion Americanscosting society about $billion annuallyDespite numerous pharmacological and non pharmacological therapiesoverof chronic pain sufferers feel little control over their painThe need for alternativemore effective pain therapies is urgentas the U Sfaces a widening prescription opioid abuse epidemicCognifiSense has developed a patent pend ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Antibody for RSV IIB
SBC: TRELLIS BIOSCIENCE, INC. Topic: RAbstract Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in infants, leading annually to ~200,000 deaths and 3-4 million hospitalizations worldwide. Close to $1 billion has been invested by the RSV community over the past two decades in clinical trials seeking to improve upon the marketed monoclonal antibody Synagis®, which is only approved for prop ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health